Back to Research Hub
Phathom Pharmaceuticals, Inc.
PHAT
$9.82-0.18 (-1.80%)
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in…
StreetsValue research for Phathom Pharmaceuticals, Inc. (PHAT)
Members get the full report for Phathom Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.